Connor, Clark & Lunn Investment Management (CC&L)
ALPN

Connor, Clark & Lunn Investment Management (CC&L)’s Alpine Immune Sciences Inc ALPN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,357
Closed -$529K – 1764
2024
Q1 		$529K Buy
13,357
+1,448
+12% +$42.7K ﹤0.01% 1089
2023
Q4 		$227K Sell
11,909
-33,566
-74% -$466K ﹤0.01% 1236
2023
Q3 		$521K Sell
45,475
-1,118
-2% -$13.8K ﹤0.01% 1002
2023
Q2 		$479K Sell
46,593
-7,644
-14% -$68.9K ﹤0.01% 993
2023
Q1 		$419K Sell
54,237
-4,071
-7% -$32.4K ﹤0.01% 932
2022
Q4 		$429K Buy
58,308
+802
+1% +$5.13K ﹤0.01% 906
2022
Q3 		$414K Buy
57,506
+7,317
+15% +$60.3K ﹤0.01% 857
2022
Q2 		$427K Buy
50,189
+21,873
+77% +$189K ﹤0.01% 817
2022
Q1 		$254K Buy
28,316
+9,290
+49% +$80.3K ﹤0.01% 908
2021
Q4 		$264K Buy
+19,026
New +$236K ﹤0.01% 914
2017
Q2 		– Sell
-14,450
Closed -$169K – 979
2017
Q1 		$169K Buy
+14,450
New +$146K ﹤0.01% 815

Connor, Clark & Lunn Investment Management (CC&L)'s ALPN Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 13,357 shares — an estimated $529K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ALPN in Q1 2017 and held it in 11 quarters. The position peaked at $529K in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 13,357 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $529K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Alpine Immune Sciences Inc in Q1 2017 and held it in 11 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Alpine Immune Sciences Inc position peaked at $529K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.